Topic: IMP

Imexpharm aims for VND2,981 billion in total revenue and VND493.5 billion in profit before tax in 2025, focusing on high-tech products, R&D, and market expansion.

Imexpharm kicked off Q1 2025 with impressive results, reporting net revenue of VND594 billion and profit before tax of VND95 billion in Q1 2025, up 21 per cent and 23 per cent year-on-year (YoY), respectively.

The long-term growth prospects of Vietnamese pharmaceutical companies are on the rise as they establish their position in the high-tech product segment, competing in both domestic and international markets.